Abstract 2342
Background
The FIRSTANA trial compared docetaxel 75mg/m2 Q3W (D75), cabazitaxel 20mg/m2 Q3W (C20) and cabazitaxel 25mg/m2 Q3W (C25) in patients with chemo-naive mCRPC (Oudard 2017). FIRSTANA enrolled patients regardless of presence of disease-related symptoms. This post-hoc analysis of FIRSTANA evaluates the influence of progression type on outcomes.
Methods
Patient outcomes (OS, PSA response [confirmed PSA decline from baseline ≥ 50%] and radiological PFS [rPFS]) were analyzed according to progression type at randomization. Progression at randomization was defined as follows: PSA progression only (PSA-p) with no radiological progression (Radio-p) and no pain, Radio-p (± PSA-p, no pain), pain progression (mean Present Pain Intensity ≥2 and/or mean analgesic score ≥ 10 over the 7 days prior to randomization (±PSA-p, ±Radio-p).
Results
PSA-p, Radio-p and Pain-p were present in 34.4%, 23.2% and 42.3% of patients at randomization, respectively. Pain progression at initiation of chemotherapy was associated with features of aggressive disease and a shorter OS. Lower activity of C20 than C25 and D75 was observed in patients with Pain-p.Table:
859P
Progression type | ||||
---|---|---|---|---|
PSA-p N = 362 | Radio-p N = 244 | Pain-p N = 445 | Global p° | |
- PSA decrease ≥ 50% - Overall - D75 - C20 - C25 | 69.0% 67.4% 71.0% 69.0% | 69.8% 65.8% 66.2% 78.3% | 58.0% 62.2% 49.3% 63.0% | P = 0.003 P = 0.70 P = 0.002 P = 0.21 |
-rPFS, median [95% CI]* - Overall - D75 - C20 - C25 | 16.5 [14.3; 18.9] 13.5 [11.3; 16.7] 19.7 [14.3; 26.5] 18.2 [14.2; 22.6] | 12.1 [11.2; 14.4] 11.3 [9.7; 14.4] 13.4 [10.6; 22.8] 11.4 [10.1; 15.7] | 10.8 [9.3;11.6] 11.4 [8.8; 13.9] 9.1 [7.6; 10.9] 11.1 [9.7; 12.8] | p < 0.001 p = 0.13 p < 0.001 p = 0.001 |
OS, median [95% CI]* - Overall - D75 - C20 - C25 | 27.7 [25.4;31.2] 29.0 [22.6; 36.6] 30.0 [24.9; NR] 26.5 [24.0; 31.6] | 30.6 [26.8;34.3] 28.4 [22.0; 34.1] 32.1 [27.9; 41.4] 29.7 [24.0; 38.5] | 18.5 [16.8; 20.6] 20.3[16.5;24.3] 16.5[14.3; 19.1] 20.4[17.0;25.3] | p < 0.001 p = 0.003 p < 0.001 p = 0.031 |
in months, NR: not reached; °Log rank test for rPFS and OS, CMH test adjusted on stratification factors
Conclusions
Most patients in FIRSTANA had pain progression at randomization and this factor was associated with worse OS. In this post-hoc, subgroup analysis, C20 appeared less active than D75 and C25 in men with baseline pain progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nicolas Delanoy.
Funding
Sanofi.
Disclosure
N. Delanoy: Travel / Accommodation / Expenses: Sanofi; Honoraria (self): Tesaro; Honoraria (self): MSD. D. Robbrecht: Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy: Bayer. K. Fizazi: Honoraria (self): Amgen; Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Clovis; Honoraria (self): CureVac; Honoraria (self): Essa; Honoraria (self): Genentech; Honoraria (self): Janssen; Honoraria (self): MSD; Honoraria (self): Orion; Honoraria (self): Sanofi. F. Mercier: Honoraria (self): Sanofi; Honoraria (self): AstraZeneca; Shareholder / Stockholder / Stock options, Stat Process is a CRO providing statistical services to various companies: Stat Process. O. Sartor: Shareholder / Stockholder / Stock options: Eli Lilly; Shareholder / Stockholder / Stock options: GlaxoSmithKline; Shareholder / Stockholder / Stock options: Noria; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Bellicum; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Johnson &Johnson; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Dendreon; Advisory / Consultancy, Research grant / Funding (institution): Endocyte; Advisory / Consultancy: Constellation Pharmaceuticals; Advisory / Consultancy: Advanced Accelerator Applications; Advisory / Consultancy: Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Bavarian Nordic; Advisory / Consultancy: Oncogenex; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Progenics. R. de Wit: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genentech. S. Oudard: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Honoraria (self): Bayer; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Ipsen.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract